Researchers have identified a potential treatment strategy for Rett syndrome via alternative splicing modulation of the MECP2 gene.

Researchers review the future of schizophrenia treatment, highlighting TAAR1 agonists, NMDA enhancers, and the gut-brain axis as key new frontiers.

Dr. Sharief Taraman, MD, DABPN, DABPM, FAAP, is CEO of Cognoa, a leading early childhood development & pediatric behavioral health company. Neurodevelopment refers to the brain’s growth and maturation ...

Jane, Julie, and Jemma are 6-year-old classmates. The three girls show several similarities in behaviour and cognition. All three struggle with starting new tasks, task-switching, sustaining attention ...

LONDON, ENFIELD, UNITED KINGDOM, October 25, 2024 /EINPresswire.com/ -- QPAN ® (QEEG-Guided Personalized AI-Based Neuromodulation) & Neuromap ®: AI-Powered ...

Non-invasive brain stimulation (NIBS) technologies are rapidly gaining prominence as effective tools for both investigating and modulating brain activity. As these technologies advance and evolve, ...

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...